Does letrozole have any place in adjuvant setting in breast cancer patients with documented hypercoagulability?
Oyan
Basak
B
Altundag
Kadri
K
Ozisik
Yavuz
Y
D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000150:complications* / Q000188:drug therapy*; D000075202:Contraindications; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000077289:Letrozole; D009570:Nitriles / Q000627:therapeutic use*; D011655:Pulmonary Embolism / Q000209:etiology*; D012306:Risk; D013629:Tamoxifen / Q000009:adverse effects; D014230:Triazoles / Q000627:therapeutic use*; D020246:Venous Thrombosis / Q000150:complications* / Q000188:drug therapy; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D014859:Warfarin; D000077289:Letrozole